PEVIA

Pan Ebola vaccine innovative approach
PEVIA logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 8
Grant agreement number
116088

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
6 189 570
EFPIA in kind
6 068 591
Other
5 473 237
Total Cost
17 731 398

Summary

The devastating Ebola outbreak that struck western Africa in 2014-2016 left over 11 000 dead, including many medical workers. The outbreak highlighted the urgent need for safe, effective vaccines against the highly infectious disease.

There are a number of promising Ebola vaccines in development, and studies suggest that they are both safe and effective. Nevertheless, their large-scale deployment could be limited by issues such as the fact that they need to be stored at extremely low temperatures (-80°C). The goal of the PEVIA project is to develop second generation Ebola vaccines based on the proteins found on the surface of the virus. The project team is using the prime-boost approach, in which one vaccine is given to prime the immune system, and a second (different) vaccine is given to boost the immune response. The project hopes that the resulting regimen will be better suited to large-scale vaccination programmes in sub-Saharan countries, most notably because it will not require storage at low temperatures. In addition, PEVIA aims to develop innovative tools and methods to facilitate the development of new vaccine candidates for Ebola and related diseases, as well as novel diagnostic tests that can be deployed in the field.

Participants Show participants on map

EFPIA companies
  • Vaxeal Research, Evry, France
Universities, research organisations, public bodies, non-profit groups
  • Assistance Publique - Hopitaux De Paris, Paris, France
  • Bernhard-Nocht-Institut Fuer Tropenmedizin, Hamburg, Germany
  • Centre Hospitalier Regional Et Universitaire De Lille, Lille, France
  • Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  • Centre National De La Recherche Scientifique Cnrs, Paris, France
  • Commissariat A L Energie Atomique Et Aux Energies Alternatives, Paris, France
  • Heinrich-Pette Institut Leibniz Institut Fuer Experimentelle Virologie, Hamburg, Germany
  • Ifakara Health Institute Trust, Dar es Salaam, Tanzania (United Republic of)
  • Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Rome, Italy
  • Istituto Superiore Di Sanita, Roma, Italy
  • Universite D'Abomey-Calavi, Cotonou, Benin
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Excellgene SA, Monthey, Switzerland
  • Oligovax, Paris, France
Third parties
  • Institut National De La Sante Et De La Recherche Medicale, Paris, France

CONTACT

Project coordinator
Estelle ZIEGLER
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
estelle.ziegler[at]aphp.fr